Vergelijking

Enfuvirtid vs. Pasireotid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

159519-65-0

396091-73-9

Molecuulmassa

4491.88 g/mol

1047.21 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Enfuvirtid

Enfuvirtide binds the first heptad-repeat region (HR1) of the gp41 subunit of the HIV envelope protein. This prevents the conformational change required for fusion of the viral and cell membranes — the virus cannot enter the cell.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Enfuvirtid	Pasireotid
Duitsland	Op recept	Op recept
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Enfuvirtid

Volledige vermelding →

Pasireotid

Volledige vermelding →

Frequently asked questions

What is the difference between Enfuvirtid and Pasireotid?: Enfuvirtid is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Enfuvirtid or Pasireotid?: The highest available evidence level is "Humane RCT" for Enfuvirtid and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Enfuvirtid and Pasireotid in Germany and the United States?: Duitsland: Enfuvirtid — Op recept, Pasireotid — Op recept. Verenigde Staten: Enfuvirtid — Op recept, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Enfuvirtid

Pasireotid

Duitsland

Op recept

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Enfuvirtid and Pasireotid?

Enfuvirtid is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Enfuvirtid or Pasireotid?

The highest available evidence level is "Humane RCT" for Enfuvirtid and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Enfuvirtid and Pasireotid in Germany and the United States?

Duitsland: Enfuvirtid — Op recept, Pasireotid — Op recept. Verenigde Staten: Enfuvirtid — Op recept, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.